Drugs / Seliciclib
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01333423 | Sep 2012 → Sep 2015 | breast cancer | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded |
| Phase 1 | NCT00999401 | Apr 2009 → Jul 2019 | cancer | Cyclacel Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT03774446 | Nov 2018 → Aug 2026 overdue | Cushing syndrome | Cedars-Sinai Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT02649751 | Feb 2016 → Jul 2018 | cystic fibrosis | University Hospital, Brest | Terminated | No outcome recorded |
| Phase 2 | NCT02160730 | May 2014 → Oct 2018 | Cushing disease due to pituitary adenoma | Shlomo Melmed, MD | Terminated | No outcome recorded |
| Phase 2 | NCT00761709 | Jul → Oct 2009 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00372073 Comparator | Aug 2006 → Mar 2009 | non-small cell lung carcinoma | Cyclacel Pharmaceuticals, Inc. | Terminated | No outcome recorded |
Evidence & citations 15 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | seliciclib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00999401 ↗ |
| Known as | AL-39256 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00761709 ↗ |
| Known as | CYC-202 | ChEMBL registry synonym — accepted as the source's own label CHEMBL14762 ↗ |
| Known as | NSC-701554 | ChEMBL registry synonym — accepted as the source's own label CHEMBL14762 ↗ |
| Known as | R-roscovitine | “The orally available kinase inhibitor R-roscovitine has undergone clinical trials against various cancers and is currently under clinical evaluation against Cushing disease and...” PMID 34961705 ↗ Dec 2021 |
| Known as | Roscovitin | ChEMBL registry synonym — accepted as the source's own label CHEMBL14762 ↗ |
| Known as | Roscovitine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02649751 ↗ |
| Action | Inhibit | “Cyclin-dependent kinase 2 inhibitor” CHEMBL14762 ↗5“Cyclin-dependent kinase 5 inhibitor” CHEMBL14762 ↗ “Cyclin-dependent kinase 7 inhibitor” CHEMBL14762 ↗ “Cyclin-dependent kinase 9 inhibitor” CHEMBL14762 ↗ “Cyclin-dependent kinase 1 inhibitor” CHEMBL14762 ↗ “a Selective CDK Inhibitor” NCT02160730 ↗ |
| Modality | Small molecule | — CHEMBL14762 ↗ |
| Route | Oral | “Oral seliciclib at 1200mg b.i.d. for 3 consecutive days as an outpatient beginning on day 1 every 2 weeks for 3 cycles as run-in.” NCT00372073 ↗ |
| Target | CDK1 | “Cyclin-dependent kinase 1 inhibitor” CHEMBL14762 ↗ |
| Target | CDK2 | “Cyclin-dependent kinase 2 inhibitor” CHEMBL14762 ↗ |
| Target | CDK5 | “Cyclin-dependent kinase 5 inhibitor” CHEMBL14762 ↗ |
| Target | CDK7 | “Cyclin-dependent kinase 7 inhibitor” CHEMBL14762 ↗ |
| Target | CDK9 | “Cyclin-dependent kinase 9 inhibitor” CHEMBL14762 ↗ |